"Continuity guaranteed" in changes at UK's Human Genetics Commission:
This article was originally published in Clinica
Executive Summary
Baroness Helena Kennedy has today stepped down as chair of the UK's Human Genetics Commission, a post she has held since its creation in 1999. Vice-chair Sir John Sulston is to take over, pending the appointment of her replacement, the HGC announced at its 29th Plenary meeting, being held today in Durham. Sir John and commission members Dr Paul Debenham, Professor John Harris and Mr Michael Harrison have been re-appointed "to ensure continuity of the HGC's work". This centres around analysing current and potential developments in human genetics, so as to advise the government on their likely impact on healthcare and to help define strategic priorities for genetic services in the NHS and for R&D, among other things.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.